Clearside Biomedical, Inc. (CLSD) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CLSD Revenue Growth
Revenue Breakdown (FY 2024)
CLSD's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CLSD Revenue Analysis (2013–2024)
As of May 8, 2026, Clearside Biomedical, Inc. (CLSD) generated trailing twelve-month (TTM) revenue of $3.3 million, reflecting significant decline in growth of -80.6% year-over-year. The most recent quarter (Q3 2025) recorded $201,000 in revenue, down 59.1% sequentially.
Looking at the longer-term picture, CLSD's 5-year compound annual growth rate (CAGR) stands at -5.2%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $29.6 million in 2021.
Revenue diversification analysis shows CLSD's business is primarily driven by License (71%), and Product and Service, Other (29%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including OCUL (-12.8% YoY), ADVM (-100.0% YoY), and NVCR (+8.5% YoY), CLSD has underperformed the peer group in terms of revenue growth. Compare CLSD vs OCUL →
CLSD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CLSDCurrent | $3M | -80.6% | -5.2% | -1735.7% | |
 OCUL | $52M | -12.8% | +24.4% | -521.0% | |
 ADVM | $1M | -100.0% | +32.0% | -13915.9% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% |
CLSD Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.7M | -79.8% | $1.5M | 91.0% | $-28,882,000 | -1735.7% |
| 2023 | $8.2M | +519.9% | $7.9M | 95.7% | $-24,844,000 | -302.0% |
| 2022 | $1.3M | -95.5% | $1.1M | 84.6% | $-30,277,000 | -2281.6% |
| 2021 | $29.6M | +274.7% | $29.6M | 100.0% | $-627,000 | -2.1% |
| 2020 | $7.9M | +263.3% | $7.9M | 100.0% | $-17,935,000 | -227.2% |
| 2019 | $2.2M | +7143.3% | $2.2M | 100.0% | $-30,304,000 | -1394.6% |
| 2018 | $30K | -91.3% | $30K | 100.0% | $-82,945,000 | -276483.3% |
| 2017 | $345K | -33.7% | $345K | 100.0% | $-58,408,000 | -16929.9% |
| 2016 | $520K | - | $520K | 100.0% | $-25,198,000 | -4845.8% |
| 2015 | $0 | - | $-33,000 | - | $-17,317,000 | - |
See CLSD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CLSD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CLSD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCLSD — Frequently Asked Questions
Quick answers to the most common questions about buying CLSD stock.
Is CLSD's revenue growth accelerating or slowing?
CLSD revenue declined -80.6% year-over-year, contrasting with the 5-year CAGR of -5.2%. TTM revenue fell to $3M. This reverses the prior growth trend.
What is CLSD's long-term revenue growth rate?
Clearside Biomedical, Inc.'s 5-year revenue CAGR of -5.2% reflects the variable expansion pattern. Current YoY growth of -80.6% is below this long-term average.
How is CLSD's revenue distributed by segment?
CLSD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.